source
- GSK pays $12 million to Wave for liver-focused siRNA program, expanding its RNA drug pipelineGSK is paying Wave Life Sciences $12 million upfront to take ownership of a hepatic program that emerged from their long‑running collaboration. The payment follows a 2022 agreement in which GSK pa…
- Merck reports positive mid-stage results for Prometheus' tulisokibart in painful skin diseaseMerck presented new data from a mid-stage trial of tulisokibart, a drug acquired through its $10.8 billion purchase of Prometheus Biosciences. The trial evaluated multiple dose levels in patients…